Detalles de la búsqueda
1.
Survival with Cemiplimab in Recurrent Cervical Cancer.
N Engl J Med;
386(6): 544-555, 2022 02 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35139273
2.
Patterns of major cutaneous surgeries and reconstructions in patients with cutaneous squamous cell carcinoma in the USA.
Future Oncol;
20(11): 691-701, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-37994593
3.
Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of ≥50%: The EMPOWER-Lung 1 study.
Cancer;
129(1): 118-129, 2023 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36308296
4.
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.
Lancet;
397(10274): 592-604, 2021 02 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-33581821
5.
Cost-Effectiveness of Cemiplimab Versus Standard of Care in the United States for First-Line Treatment of Advanced Non-small Cell Lung Cancer With Programmed Death-Ligand 1 Expression ≥50.
Value Health;
25(2): 203-214, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35094793
6.
Hedgehog pathway inhibitor real-world treatment patterns in patients with basal cell carcinoma: a claims-based analysis.
Future Oncol;
18(23): 2561-2572, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35735026
7.
A call to action to harmonize patient-reported outcomes evidence requirements across key European HTA bodies in oncology.
Future Oncol;
18(29): 3323-3334, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-36053168
8.
Assessing the Value of Cemiplimab for Adults With Advanced Cutaneous Squamous Cell Carcinoma: A Cost-Effectiveness Analysis.
Value Health;
24(3): 377-387, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33641772
9.
Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma.
Future Oncol;
17(5): 611-627, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33052055
10.
CASE (CemiplimAb-rwlc Survivorship and Epidemiology) study in advanced cutaneous squamous cell carcinoma.
Future Oncol;
16(4): 11-19, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-31951149
11.
Phase 2 open-label, multicenter, single-arm study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Extended follow-up.
J Am Acad Dermatol;
90(2): 414-418, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37839734
12.
The health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) during an annual influenza epidemic and influenza pandemic in China.
BMC Infect Dis;
15: 284, 2015 Jul 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-26206275
13.
The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ethnic group and age: results from OAB-POLL.
Neurourol Urodyn;
32(3): 230-7, 2013 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-22847394
14.
Real-world analysis of cost, treatment patterns, and outcomes of patients with metastatic cutaneous squamous cell carcinoma in the US.
Expert Rev Pharmacoecon Outcomes Res;
23(8): 911-920, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37313647
15.
Qualitative Patient Interviews to Characterize the Human Burden of Advanced Basal Cell Carcinoma Following Hedgehog Pathway Inhibitor Treatment.
Dermatol Ther (Heidelb);
13(8): 1747-1761, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37330458
16.
Real-World Treatment Patterns After CD19-Directed CAR T Cell Therapy Among Patients with Diffuse Large B Cell Lymphoma.
Adv Ther;
39(6): 2630-2640, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35397110
17.
Real-World Treatment Patterns and Outcomes Among Patients with Basal Cell Carcinoma Following First-Line Hedgehog Inhibitor Discontinuation.
Dermatol Ther (Heidelb);
12(5): 1211-1224, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35507216
18.
Patient-reported outcomes labeling for oncology drugs: Multidisciplinary perspectives on current status and future directions.
Front Pharmacol;
13: 1031992, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36339622
19.
Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50.
Ther Adv Med Oncol;
14: 17588359221105024, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35747163
20.
EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer.
Eur J Cancer;
174: 299-309, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35922251